Study to Investigate the Effects Single Oral Dose of AZD1386 (Capsaicin)
Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Capsaicin Evoked Pain; Heat Sensitivity
Intervention: AZD1386 (Drug); Placebo (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s): Agneta Berg, Study Chair, Affiliation: AstraZeneca R&D Södertälje Ingemar Bylesjö, Principal Investigator, Affiliation: AstraZeneca R&D CPU Karolinska University Hospital, Stockholm
Summary
A double-blind, randomized, single-centre, placebo-controlled, crossover study to
investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked
pain symptoms and heat sensitivity in healthy volunteers
Clinical Details
Official title: A Double-Blind, Randomized, Single-Centre, Placebo-Controlled, Crossover Study to Investigate the Effects of a Single Oral Dose of AZD1386 on Intradermal Capsaicin Evoked Pain Symptoms and Heat Sensitivity in Healthy Volunteers
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: VAS, HPT
Secondary outcome: eVAS, HPT, Laser Doppler imaging,WDT, Somedic allodyniaVital signs, laboratory variables and adverse event each day throughout the study. paper printout ECG and/or digital ECG throughout the study. Pain evoked assessments visit 1-3 Pharmacokinetics/Pharmacodynamics
Eligibility
Minimum age: 20 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical normal physical findings, including BP, pulse rate >45 bpm, ECG and
laboratory assessments
- Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg.
- Non-fertile females
Exclusion Criteria:
- History of hypersensitivity, allergy or atopic/skin disease as judged by
Investigator.
- History of somatic or psychiatric disease/condition, which may interfere with the
objectives of the study as judged by the Investigator.
Locations and Contacts
Additional Information
Starting date: January 2008
Last updated: June 5, 2008
|